Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMED9QV)

Drug Name

INCB40093 Drug Info

Synonyms

Dezapelisib; 1262440-25-4; UNII-2K59L7G59M; CHEMBL2216863; INCB040093; 2K59L7G59M; Dezapelisib (USAN); Dezapelisib [USAN]; (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one; SCHEMBL975754; GTPL9728; INCB40093; RSIWALKZYXPAGW-NSHDSACASA-N; INCB 40093; BDBM50004547; SB18837; example 15 [WO2011008487]; compound 67 [PMID: 22924688]; D10924; 6-(3-fluorophenyl)-3-methyl-7-[(1S)-1-(7H-purin-6-ylamino)ethyl]-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one; 6-(3-fluorophenyl)-3-methyl-7-((1S)-1-(9

Indication

Disease Entry	ICD 11	Status	REF
Lymphoma	2A80-2A86	Phase 1/2	[1]

Cross-matching ID

PubChem CID: 58111426
CAS Number: CAS 1262440-25-4
TTD Drug ID: DMED9QV

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting PI3-kinase delta (PIK3CD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY 80-6946	DMLOS5R	Follicular lymphoma	2A80	Approved	[3]
Idelalisib	DM602WT	Chronic lymphocytic leukaemia	2A82.0	Approved	[4]
Umbralisib	DMYRBO1	Follicular lymphoma	2A80	Approved	[5]
IPI-145	DMWA24P	Follicular lymphoma	2A80	Approved	[6]
Leniolisib	DMWAD93	Stomach cancer	2B72	Approved	[7]
Buparlisib	DM1WEHC	Breast cancer	2C60-2C65	Phase 3	[8]
INCB50465	DMZJP2T	Diffuse large B-cell lymphoma	2A81	Phase 2	[9]
ME-401	DMK0UOY	Follicular lymphoma	2A80	Phase 2	[9]
RP6530	DMYILGK	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[9]
Parsaclisib	DMYBIFS	Follicular lymphoma	2A80	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PI3-kinase delta (PIK3CD)	TTGBPJE	PK3CD_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038471)
2	INCB40093 is a selective PI3Kdelta inhibitor with potent antiproliferative activity against human B-cell tumors.
3	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
4	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
6	PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
7	Effective "activated PI3K syndrome"-targeted therapy with the PI3K inhibitor leniolisib. Blood. 2017 Nov 23;130(21):2307-2316.
8	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	Parsaclisib, a potent and highly selective PI3K inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019 Apr 18;133(16):1742-1752.